Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.

Trial Details

NCT ID
NCT05983237
Phase
PHASE1 / PHASE2
Sponsor
Jun Guo
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Fluzoparib Camrelizumab Temozolomide
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically confirmed diagnosis of unresectable or metastatic stage III or IV melanoma;
  • Must have genetic HR and/or SF3B1 mutation/ alteration;
  • Must have measurable disease based on RECIST 1.1;
  • Must have an ECOG performance status of 0 to 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →